Rogosin Institute

The Rogosin Institute is a national leader in the prevention, detection, and management of chronic and end-stage kidney disease.

Since 1987, The Starr Foundation has donated more than $36 million to support the Institute’s mission of providing patients with state-of-the-art treatment options and playing a formative role in advancing innovative clinical research.

Two major Starr-funded initiatives, the Stuart Saal Endowed Research Fund and the Saal-Greenberg Fund, support research priorities identified by leading nephrologist Dr. Stuart D. Saal, including renal disease, diabetes, aging, and acute and chronic kidney injury. The Saal-Greenberg Fund includes additional emphasis on patient outreach and education programs to encourage greater patient involvement in their own care; this includes the adoption of home dialysis, which can optimize lifestyle choices and improve clinical outcomes. The Fund also supports the expansion of Rogosin’s Prevention and Education in Advanced Kidney Disease (PEAK) program, which helps patients manage and, in some instances, slow the progression of their disease, which may lead to earlier transplantation and higher rates of home dialysis and a robust Wellness Website for chronic kidney disease patients.

Significant Starr grants also supported the Maurice Greenberg Comprehensive Lipid Control Center for adults and children with high levels of cholesterol. The Center was the first unit in the United States to use LDL-apheresis, a procedure pioneered by Rogosin and the Rockefeller University. With the ability to lower LDL cholesterol by more than 50%, the procedure is critical for people with inherited high cholesterol who do not respond to changes in diet and exercise, which helps to reduce their risk of developing diabetes, kidney and heart disease, and obesity. Rogosin’s programs to reverse atherosclerosis were adopted in cities nationwide.

Starr Foundation funding also supports the Maurice R. and Corinne P. Greenberg Center for Integrative Healthcare, which offers a full spectrum of chronic and end-stage kidney disease treatment and management strategies, and Rogosin’s Prevention and Education in Advanced Kidney Disease (PEAK) program. In 2018, the Center opened the first freestanding home-dialysis treatment and education center in the New York City area, helping improve the quality of life for patients with kidney disease. Rogosin has expanded, to additional New York City sites, the successful home-dialysis-center model established at the Center.

• Rogosin’s Immunogenetics and Transplantation Laboratory (IGT), which has grown into one of the largest solid-organ immunogenetics laboratories in the Northeastern United States, provides testing for more than 20 transplantation programs and three blood banks nationally.
• Rogosin’s polycystic kidney disease (PKD) data repository, one of the largest in the world, offers over 20 years of invaluable research data. This clinical laboratory for molecular biology and PKD has improved understanding of PKD and diagnostic testing through improved gene mutation analysis, and has enabled clinical trials of new therapeutic agents.